167 related articles for article (PubMed ID: 11298834)
21. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.
Di Tommaso A; Saletti G; Pizza M; Rappuoli R; Dougan G; Abrignani S; Douce G; De Magistris MT
Infect Immun; 1996 Mar; 64(3):974-9. PubMed ID: 8641809
[TBL] [Abstract][Full Text] [Related]
22. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit.
de Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
Vaccine; 1996 Mar; 14(4):260-6. PubMed ID: 8744549
[TBL] [Abstract][Full Text] [Related]
23. In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice.
Bost KL; Holton RH; Cain TK; Clements JD
Immunology; 1996 Apr; 87(4):633-41. PubMed ID: 8675220
[TBL] [Abstract][Full Text] [Related]
24. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.
Weltzin R; Guy B; Thomas WD; Giannasca PJ; Monath TP
Infect Immun; 2000 May; 68(5):2775-82. PubMed ID: 10768972
[TBL] [Abstract][Full Text] [Related]
25. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids.
Bowman CC; Clements JD
Infect Immun; 2001 Mar; 69(3):1528-35. PubMed ID: 11179323
[TBL] [Abstract][Full Text] [Related]
26. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.
Beignon AS; Briand JP; Muller S; Partidos CD
Immunology; 2002 Feb; 105(2):204-12. PubMed ID: 11872096
[TBL] [Abstract][Full Text] [Related]
27. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.
Takahashi I; Marinaro M; Kiyono H; Jackson RJ; Nakagawa I; Fujihashi K; Hamada S; Clements JD; Bost KL; McGhee JR
J Infect Dis; 1996 Mar; 173(3):627-35. PubMed ID: 8627026
[TBL] [Abstract][Full Text] [Related]
29. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
Byrd W; Boedeker EC
Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
[TBL] [Abstract][Full Text] [Related]
30. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
Tamura SI; Kurata T
Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
[TBL] [Abstract][Full Text] [Related]
31. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells.
Guebre-Xabier M; Hammond SA; Epperson DE; Yu J; Ellingsworth L; Glenn GM
J Virol; 2003 May; 77(9):5218-25. PubMed ID: 12692224
[TBL] [Abstract][Full Text] [Related]
32. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
33. Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells.
Martin M; Hajishengallis G; Metzger DJ; Michalek SM; Connell TD; Russell MW
Infect Immun; 2001 Jan; 69(1):252-61. PubMed ID: 11119513
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.
Glenn GM; Villar CP; Flyer DC; Bourgeois AL; McKenzie R; Lavker RM; Frech SA
Infect Immun; 2007 May; 75(5):2163-70. PubMed ID: 17261601
[TBL] [Abstract][Full Text] [Related]
35. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
[TBL] [Abstract][Full Text] [Related]
36. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
Tumpey TM; Renshaw M; Clements JD; Katz JM
J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
[TBL] [Abstract][Full Text] [Related]
37. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.
Scharton-Kersten T; Yu Jm; Vassell R; O'Hagan D; Alving CR; Glenn GM
Infect Immun; 2000 Sep; 68(9):5306-13. PubMed ID: 10948159
[TBL] [Abstract][Full Text] [Related]
38. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.
Dickinson BL; Clements JD
Infect Immun; 1995 May; 63(5):1617-23. PubMed ID: 7729864
[TBL] [Abstract][Full Text] [Related]
39. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.
Barackman JD; Ott G; O'Hagan DT
Infect Immun; 1999 Aug; 67(8):4276-9. PubMed ID: 10417205
[TBL] [Abstract][Full Text] [Related]
40. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
McCluskie MJ; Weeratna RD; Clements JD; Davis HL
Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
